The Future Potential of Non-Invasive Cancer Diagnostics

LONDON - Sept. 29, 2017 - PRLog -- Roots Analysis has announced the addition of "Non-invasive Cancer Diagnostics Market, 2015-2030" report to their offering. The report offers an extensive study of several commercialized and / or under development non-invasive diagnostic solutions for different types of cancer. Specifically, liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease's progress. The market is characterized by the presence of several companies that have proprietary technologies for either the isolation / enrichment / enumeration of rare circulating tumor cells (CTCs) or for the molecular characterization / sequencing of genetic material extracted from CTCs / exosomes.

Ishita Nanda, the principal analyst, said, "As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives of this report was to understand the future potential of the market. This was done by analyzing:

▪ The global burden of cancer, in terms of incidence and prevalence of different cancer indications across different geographies.

▪ The overall market landscape of liquid biopsies and other novel diagnostic tests, in terms of type of analysis (CTCs/ctDNA/exosomes), test sample source (blood/urine/others) and the disease indication.

▪ The likely evolution of the liquid biopsy market, taking into account initial diagnosis, recurrence monitoring and patient monitoring in developed geographies (US and EU28).

▪ Contribution of other novel diagnostic tests in the market and the opportunity of the key indications influencing overall growth."

Nanda added, "Our opinions and insights were influenced by discussions that we conducted with experts in this area. These included senior representatives at iCellate, MiNDERA Corporation and VolitionRx. It is important to stress that even though liquid biopsy has not yet gained a foothold in oncology, it is likely to transform the cancer diagnostics market with many commercial success stories in the foreseen future."

The 228 page report includes detailed profiles and an assessment of the various products being developed by a number of companies including:

▪ Biocept

▪ Exosome Diagnostics

▪ Genomic Health

▪ Guardant Health

▪ Qiagen

▪ bioMerieux

▪ Cepheid

▪ DermTech

▪ DiagnoCure

▪ Exact Sciences

▪ Pacific Edge

Several other companies engaged in the development of kits and assays to support the detection, isolation and characterization of the rare biomarkers have also been captured in the report. Examples include (in no specific order) ANGLE, ScreenCell, ApoCell, Clearbridge BioMedics, iCellate.

For additional details, please visit

http://www.rootsanalysis.com/reports/view_document/non-in...

or email sales@rootsanalysis.com